Hosted on MSN19h
Jefferies Upgrades Crinetics Pharmaceuticals (CRNX)
Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from ...
Crinetics upgraded to buy by Jefferies, atumelnant potential cited
Jefferies has upgraded Crinetics (CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant. Read more here.